Cognitive Neurology Unit Clinical Registry
ConditionAlzheimer Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-95
SponsorBeth Israel Deaconess Medical Center
About this trial
A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
Eligibility criteria
Qualifiers
o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
Patient has evidence of cognitive impairment on neuropsychological testing
Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
Disqualifiers
o Recent stroke or suspected TIA in the past year
Pregnancy
Active autoimmune or immunological disease
Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
Trial design
Treatments tested in this trial
- Lecanemab
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov